T he different Jewish ethnic groups were isolated from the surrounding non-Jewish populations as a result of religious restrictions and cultural differences, and from each other by geographical boundaries. [1] [2] [3] Thus, their respective genetic loads differ, except for more ancient founder mutations common in all Jews that were acquired before the communities dispersed. 2 With the establishment of the State of Israel in 1948, many of these Jews migrated back to Israel. Both the mutations characteristic to the specific ethnic groups and the common Jewish mutations created the basis for the ethnic-specific screens offered to the different communities in Israel.
As expected, the incidence and distribution of mutations of cystic fibrosis (CF) vary between the Jewish ethnic communities. 4 A carrier CF screening was introduced in Israel once the major mutations in the various ethnic groups were identified. 4, 5 This screen was possible for the Ashkenazi, North African, Sephardic and Georgian Jews, for whom the tested mutations gave a high detection rate. 4 As carrier frequencies are high in these groups, screening was provided to couples from the same or mixed origins. The population study described here was initiated to determine the carrier frequencies of recently identified mutations in CF patients of Oriental origin. 6 It is based on data collected from genetics laboratories at 10 Israeli medical centers.
MATERIALS AND METHODS

Participating centers
Data were collected from 10 medical centers that performed carrier screening for CF: Assaf Harofeh (Zerifin), Bnei Zion 
Subjects
Data related to four Oriental mutations were collected from a total of 2499 individuals of homogeneous or mixed Iraqi origin, and 1435 individuals of homogeneous or mixed Yemenite origin. Definition of origin was based on individuals' reports at the time of blood collection. Participants were healthy individuals who performed the screening tests in a family planning context; therefore, some of the subjects were pregnant women. Individuals with signs of CF, or family history of CF were excluded from the study. Informed consent was obtained from all participants and the study was approved by the Institutional Review Board. 
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Genetic analysis
The Oriental Jewish mutations, 3121-1G Ͼ A, Y1092X, and 2751 ϩ 1insT, were tested on samples from Iraqi Jews, and the I1234V mutation was tested on Yemenite Jews. Genetic analysis consisted of polymerase chain reaction amplification followed by restriction enzyme analysis, 5 using primers and enzymes listed in Table 1 . For each mutation, the number of tested individuals and carriers from each origin was reported. The total number of alleles was calculated as follows: when origin was homogeneous, by multiplying the number of screened individuals by two (for two alleles per one subject); when origin was mixed, by multiplying the number of screened individuals by only the fraction of the origin under consideration.
RESULTS
The three founder Oriental Jewish mutations, Y1092X, 3121-1G Ͼ A, and 2751 ϩ 1insT, were tested on 3474, 890, and 992 screened alleles of Jewish Iraqi origin, respectively; the I1234V mutation was tested on 2072 screened alleles of Yemenite origin (Table 2 ). In the absence of consensus on the mutation repertoire of the Oriental Jewish groups before this study, the number of mutations examined by each of the participating centers varied. The different numbers of total tested alleles for each mutation accounts for the different denominators in Table 2 .
In the Iraqi Jewish population, the 3121-1G Ͼ A mutation was the most frequent, with a carrier frequency of 1:68.5. The Y1092X mutation had a lower carrier frequency of 1:435, and the 2751 ϩ 1insT mutation was not detected at all. In the Yemenite Jewish population, the I1234V mutation had a carrier frequency of 1:130.
DISCUSSION
A unique mutation spectrum for CF had been found previously in each of the Jewish communities, and for each community the detection rate differed. Five mutations provide at least a 95% detection rate among Ashkenazi Jewish CF patients, 4 and additional specific mutations were found among Tunisian, Libyan, Moroccan, Turkish, and Georgian Jews, giving higher than 85% detection rates in these populations. 4, 6 The disease frequency in these communities is similar to that of the non-Jewish white frequency (1:2,400 -1:3,300). 7 The high incidence and rate of detection of the major mutations among these specific Jewish communities prompted the introduction of a carrier screening program in Israel in 1995, 4, 8 according to the policy established by the Israeli Society of Medical Geneticists (ISMG). This initial policy recommended screening Ashkenazi Jews for their five founder mutations, and adding the mutations specific to the non-Ashkenazi Jewish group to the screen. For example, for Tunisian Jews the 405 ϩ 1G Ͼ A mutation was added to the five Ashkenazi mutations, and for Moroccan Jews the S549R and D1152H mutations were added to the five Ashkenazi mutations. 8 Because approximately 25% of all marriages in Israel is intercommunal, 9 changing the population admixture, the ISMG simplified the carrier protocol of CF screening in the year 2002: all non-Ashkenazi Jews were grouped together (not including the Oriental Jews because of lack of information) and were screened for a total of nine mutations-the five Ashkenazi and the four known non-Ashkenazi mutations (405 ϩ 1G Ͼ A S549R, W1089X, G85E).
Jews of Georgian origin were tested for the five Ashkenazi mutations and the typical Georgian mutation (T360K). Accumulating information led to removal of 1717-1 G Ͼ A from the carrier screen because of its rarity, 8 and D1152H because of the mild phenotype. 10 To increase the detection rate, when a carrier was detected in the screen, his or her partner was evaluated for at least those nine mutations, even if of Ashkenazi or Georgian origin. 
